Ipsen SA - Asset Resilience Ratio

Latest as of June 2025: 21.63%

Ipsen SA (IPN) has an Asset Resilience Ratio of 21.63% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Ipsen SA to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€1.48 Billion
≈ $1.73 Billion USD Cash + Short-term Investments

Total Assets

€6.83 Billion
≈ $7.99 Billion USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2002–2024)

This chart shows how Ipsen SA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Ipsen SA (IPN) total assets.

Liquid Assets Composition Over Time

This chart breaks down Ipsen SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Ipsen SA strategic investment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €1.45 Billion 21.16%
Short-term Investments €32.30 Million 0.47%
Total Liquid Assets €1.48 Billion 21.63%

Asset Resilience Insights

  • Good Liquidity Position: Ipsen SA maintains a healthy 21.63% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Ipsen SA Industry Peers by Asset Resilience Ratio

Compare Ipsen SA's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
Drug Manufacturers - Specialty & Generic 4.94%
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Piramal Pharma Limited
NSE:PPLPHARMA
Drug Manufacturers - Specialty & Generic 0.73%
Kangmei Pharmaceutical Co Ltd
SHG:600518
Drug Manufacturers - Specialty & Generic 0.00%
Zhejiang Medicine Co Ltd
SHG:600216
Drug Manufacturers - Specialty & Generic 1.85%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
Drug Manufacturers - Specialty & Generic 0.29%

Annual Asset Resilience Ratio for Ipsen SA (2002–2024)

The table below shows the annual Asset Resilience Ratio data for Ipsen SA.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 0.02% €1.10 Million
≈ $1.29 Million
€6.44 Billion
≈ $7.53 Billion
-0.15pp
2023-12-31 0.17% €10.60 Million
≈ $12.39 Million
€6.32 Billion
≈ $7.39 Billion
-21.24pp
2022-12-31 21.40% €1.20 Billion
≈ $1.40 Billion
€5.61 Billion
≈ $6.56 Billion
+4.23pp
2021-12-31 17.17% €857.10 Million
≈ $1.00 Billion
€4.99 Billion
≈ $5.83 Billion
+16.55pp
2020-12-31 0.62% €26.80 Million
≈ $31.33 Million
€4.31 Billion
≈ $5.04 Billion
-3.96pp
2019-12-31 4.58% €197.20 Million
≈ $230.55 Million
€4.31 Billion
≈ $5.04 Billion
-1.57pp
2018-12-31 6.15% €207.70 Million
≈ $242.82 Million
€3.38 Billion
≈ $3.95 Billion
-2.98pp
2017-12-31 9.13% €280.60 Million
≈ $328.05 Million
€3.07 Billion
≈ $3.59 Billion
-5.91pp
2016-12-31 15.04% €364.50 Million
≈ $426.14 Million
€2.42 Billion
≈ $2.83 Billion
+14.69pp
2015-12-31 0.35% €6.80 Million
≈ $7.95 Million
€1.94 Billion
≈ $2.27 Billion
+0.35pp
2014-12-31 0.01% €100.00K
≈ $116.91K
€1.71 Billion
≈ $2.00 Billion
-0.01pp
2013-12-31 0.01% €200.00K
≈ $233.82K
€1.57 Billion
≈ $1.83 Billion
-0.02pp
2012-12-31 0.03% €516.00K
≈ $603.26K
€1.56 Billion
≈ $1.83 Billion
+0.03pp
2011-12-31 0.00% €9.00K
≈ $10.52K
€1.63 Billion
≈ $1.91 Billion
0.00pp
2010-12-31 0.00% €49.00K
≈ $57.29K
€1.68 Billion
≈ $1.96 Billion
-0.07pp
2009-12-31 0.07% €1.16 Million
≈ $1.36 Million
€1.58 Billion
≈ $1.84 Billion
-0.09pp
2008-12-31 0.16% €2.53 Million
≈ $2.96 Million
€1.57 Billion
≈ $1.84 Billion
-0.30pp
2007-12-31 0.46% €6.10 Million
≈ $7.13 Million
€1.32 Billion
≈ $1.55 Billion
+0.39pp
2006-12-31 0.07% €901.00K
≈ $1.05 Million
€1.21 Billion
≈ $1.42 Billion
+0.07pp
2005-12-31 0.00% €18.00K
≈ $21.04K
€942.51 Million
≈ $1.10 Billion
-11.71pp
2004-12-31 11.71% €72.59 Million
≈ $84.86 Million
€619.71 Million
≈ $724.51 Million
-1.40pp
2003-12-31 13.12% €87.34 Million
≈ $102.11 Million
€665.90 Million
≈ $778.50 Million
-3.85pp
2002-12-31 16.97% €112.39 Million
≈ $131.39 Million
€662.33 Million
≈ $774.34 Million
--
pp = percentage points

About Ipsen SA

PA:IPN France Drug Manufacturers - Specialty & Generic
Market Cap
$15.02 Billion
€12.84 Billion EUR
Market Cap Rank
#2169 Global
#44 in France
Share Price
€155.90
Change (1 day)
+0.06%
52-Week Range
€111.50 - €172.90
All Time High
€172.90
About

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroendocrine tumors; Onivyde, an irinotecan liposome injec… Read more